StoryFunding
Chai Discovery raises $400M Series C at $3.8B valuation, deploys antibody-design AI with four pharma leaders
Chai Discovery closed a $400 million Series C funding round at a $3.8 billion post-money valuation, positioning it as a leading zero-shot antibody design lab. Within seven months, the company had secured paid deployments with Eli Lilly, Pfizer, Novartis, and argenx, indicating rapid adoption by major pharmaceutical companies.
- $400M Series C at $3.8B valuation
- Zero-shot antibody design without structural templates
- Paid deployments with four major pharma companies within 7 months
- Addresses antibody discovery, a critical drug-development bottleneck